Anagrelid

Anagrelid
Klinički podaci
Prodajno ime	Agrylin, Xagrid
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	1,3 h
Identifikatori
CAS broj	68475-42-3
ATC kod	L01XX35 (WHO)
PubChem	CID 2182
DrugBank	DB00261
ChemSpider	2097
ChEBI	CHEBI:142290
ChEMBL	CHEMBL760
Hemijski podaci
Formula	C10H7Cl2N3O
Molarna masa	256,088
	SMILES ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl; ;
	InChI InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16) ; Key:OTBXOEAOVRKTNQ-UHFFFAOYSA-N ;
Fizički podaci
Tačka topljenja	280 °C (536 °F)

Anagrelid je organsko jedinjenje, koje sadrži 10 atoma ugljenika i ima molekulsku masu od 256,088 Da.^[1]^[2]^[3]^[4]^[5]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	3
Broj donora vodonika	1
Broj rotacionih veza	0
Particioni koeficijent^[6] (ALogP)	2,0
Rastvorljivost^[7] (logS, log(mol/L))	-2,7
Polarna površina^[8] (PSA, Å²)	44,7

Reference

^ Voglova J, Maisnar V, Beranek M, Chrobak L: [Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase] Voglová, J.; Maisnar, V.; Beránek, M.; Chrobák, L. (септембар 2006). „Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase”. Vnitr Lek. 52 (9): 819—22. PMID 17091608.
^ Petrides PE: Anagrelide: what was new in 2004 and 2005? Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):399-408. Petrides, P. E. (2006). „Anagrelide: What was new in 2004 and 2005?”. Seminars in Thrombosis and Hemostasis. 32 (4 Pt 2): 399—408. PMID 16810615. doi:10.1055/s-2006-942760.
^ Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR (јул 2005). „Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia”. N Engl J Med. 353 (1): 33—45. PMID 16000354. doi:10.1056/NEJMoa043800.
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—D1041. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—D906. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
^ Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.